Ibolex (Dexibuprofen)

Dexibuprofen works by inhibiting the cyclooxygenase (COX) enzymes, which are essential for the production of prostaglandins. By reducing prostaglandin synthesis, it lessens inflammation, pain signals, and fever responses at the site of injury.

The appropriate dose of Ibolex is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and overall health. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety of dexibuprofen in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Ibolex, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Dexibuprofen is the active S‑enantiomer of ibuprofen, offering similar analgesic and anti‑inflammatory potency with potentially improved gastrointestinal tolerability compared with the racemic mixture. Compared with other NSAIDs, its safety profile is comparable, but individual response and risk factors may differ.

Ibolex should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Ibolex is taken orally with a full glass of water. It can be taken with or without food, although taking it with food may reduce the chance of stomach upset. Swallow the tablet whole; do not crush or chew unless directed by a healthcare professional.

The most serious risks include gastrointestinal bleeding or ulceration, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, renal impairment, and increased cardiovascular events in susceptible individuals. Patients should seek immediate medical attention if they notice signs of serious bleeding, rash, or breathing difficulties.

Ibolex should be avoided in individuals with known hypersensitivity to dexibuprofen or other NSAIDs, active gastrointestinal ulcer disease, severe heart failure, uncontrolled hypertension, or significant renal or hepatic impairment unless specifically advised by a physician.